Parkinson's disease and α‐synuclein expression
Citations Over TimeTop 10% of 2011 papers
Abstract
Genetic studies of Parkinson's disease over the last decade or more have revolutionized our understanding of this condition. α-Synuclein was the first gene to be linked to Parkinson's disease, and is arguably the most important: the protein is the principal constituent of Lewy bodies, and variation at its locus is the major genetic risk factor for sporadic disease. Intriguingly, duplications and triplications of the locus, as well as point mutations, cause familial disease. Therefore, subtle alterations of α-synuclein expression can manifest with a dramatic phenotype. We outline the clinical impact of α-synuclein locus multiplications, and the implications that this has for Parkinson's disease pathogenesis. Finally, we discuss potential strategies for disease-modifying therapies for this currently incurable disorder.
Related Papers
- → O.026 Mice over-expressing wild-type human alpha-synuclein as tools for therapeutic discovery in Parkinson's disease(2009)
- → P.1.g.008 Levodopa chronic treatment promotes reinforcing properties of pramipexole in alpha-synuclein rat model of Parkinson's disease(2015)
- More than a synuclein story: Dissecting determinants for alpha-synuclein aggregation and degradation in the Parkinson’s disease brain(2020)
- → Review for "Movement of Prion-Like alpha-Synuclein along the Gut-Brain Axis in Parkinson's Disease: A Potential Target of Curcumin Treatment"(2021)
- → Decision letter for "Movement of Prion-Like alpha-Synuclein along the Gut-Brain Axis in Parkinson's Disease: A Potential Target of Curcumin Treatment"(2021)